Exactus Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
0.60
0.90
0.20
-
-
-
Cost of Goods Sold (COGS) incl. D&A
-
1.80
-
-
-
-
Gross Income
-
0.90
-
-
-
-
SG&A Expense
112.40
419.30
367.00
1,597.40
1,996.60
2,436.20
EBIT
113.40
420.30
368.40
1,597.40
1,996.60
2,436.20
Unusual Expense
-
-
10.50
4.10
1,182.30
1,041.80
Non Operating Income/Expense
89.40
123.70
-
1.50
-
-
Interest Expense
-
-
-
-
681.80
859.30
Pretax Income
23.90
296.60
358.00
1,602.90
3,860.70
4,337.30
Consolidated Net Income
23.90
296.60
358.00
1,602.90
3,860.70
4,337.30
Net Income
23.90
296.60
358.00
1,602.90
3,860.70
4,337.30
Net Income After Extraordinaries
23.90
296.60
358.00
1,602.90
3,860.70
4,337.30
Net Income Available to Common
23.90
296.60
358.00
1,602.90
3,860.70
4,337.30
EPS (Basic)
0.05
0.59
0.59
0.08
0.11
0.91
Basic Shares Outstanding
511.90
511.90
512.00
19,220.70
33,947.20
4,764.10
EPS (Diluted)
0.05
0.58
0.70
0.08
0.11
0.91
Diluted Shares Outstanding
511.90
511.90
512.00
19,220.70
33,947.20
4,764.10
EBITDA
111.80
418.50
366.80
1,597.40
1,996.60
2,436.20

About Exactus

View Profile
Address
80 NE 4th Avenue
Delray Beach Florida 33483
United States
Employees -
Website http://www.exactusinc.com
Updated 07/08/2019
Exactus, Inc. is a life science company, which engages in developing and commercializing Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a novel detection platform. It operates under the FibriLyzer and MatriLyzer trademarks. The company was founded on January 18, 2008 and is headquartered in Glen Allen, VA.